The investigation of variability of the pharmacokinetics of mesalamine from mesalamine formulations
PRESENTED TO: BioPharma Services Inc.
PRESENTED BY: Juan He*, Masood Bhatti, and Lorelei Lutter
Purpose: Mesalamine, which is also called 5-aminosalicylic acid or 5-ASA, is an amino-salicylate anti-inflammatory drug indicated for the treatment of ulcerative colitis. There are several oral delayed release and sustained release mesalamine formulations. The pharmacokinetic profiles of Asacol®, Pentasa®, and Lialda® are included in this investigation.
To access the entire publication and view the full resolution PDF, please complete the form.